17 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 20 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 17, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Neoplasms, Fibroepithelial: new trials by email Literature Review of Neoplasms, Fibroepithelial trials Research Report on Neoplasms, Fibroepithelial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) Harmonic motion imaging guided focused ultrasound (HMIgFUS), Microbubble-mediated Low Intensity Focused Ultrasound (LIFU), Microbubbles - Fibroadenoma, Breast Cancer Stage I | Phase 1 | Recruiting | Columbia University | 82 | 2022-01-19 | 2026-08-13 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer adjuvant therapy, paclitaxel, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 113 | 2004-06-01 | 2019-07-22 |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer pegfilgrastim, carboplatin, docetaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 2004-06-01 | 2010-09-21 | |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) carboplatin, paclitaxel, docetaxel - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-05-01 | 2019-07-22 |
| Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer carcinoembryonic antigen-expressing measles virus, oncolytic measles virus encoding thyroidal sodium iodide symporter, reverse transcriptase-polymerase chain reaction - Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 1 | Completed | Mayo Clinic | 37 | 2004-04-19 | 2024-01-16 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors SS1(dsFv)-PE38 immunotoxin - Cervical Cancer, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 2003-07-01 | 2015-04-30 | |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Carboplatin, Paclitaxel Poliglumex, Pharmacological Study - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 32 | 2003-04-01 | 2015-05-08 |
| Immunotoxin Therapy in Treating Patients With Advanced Cancer SS1(dsFv)-PE38 immunotoxin - Cervical Cancer, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 2000-12-01 | 2015-04-30 | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer carboplatin, paclitaxel, topotecan hydrochloride - Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 1 | Completed | Gynecologic Oncology Group | 2000-02-01 | 2013-05-27 | |
| Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer etoposide, topotecan hydrochloride - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Completed | Gynecologic Oncology Group | 24 | 1999-09-01 | 2013-05-27 |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Completed | Gynecologic Oncology Group | 48 | 1999-03-01 | 2013-05-27 |
| Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer etoposide, pegylated liposomal doxorubicin hydrochloride - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Terminated | Gynecologic Oncology Group | 1998-05-01 | 2013-06-10 | |
| Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission filgrastim, melphalan, thiotepa - Ovarian Cancer | Phase 1 | Completed | Fred Hutchinson Cancer Center | 45 | 1997-01-01 | 2010-09-15 |
| Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer paclitaxel, cisplatin, topotecan hydrochloride - Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 1996-12-01 | 2013-01-24 |
| Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer carboplatin, pegylated liposomal doxorubicin hydrochloride - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Completed | Gynecologic Oncology Group | 2013-07-09 |
Brenner Tumor (19) · Ovarian Neoplasms (16) · Fallopian Tube Neoplasms (15) · Carcinoma, Ovarian Epithelial (13) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Mesothelioma, Malignant (2) · Pancreatic Neoplasms (2) · Salivary Gland Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uterine Cervical Neoplasms (2) · Breast Neoplasms (1) · Fibroadenoma (1) · Neurotoxicity Syndromes (1)
Neoplasms (20) · Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Connective Tissue (20) · Neoplasms, Connective and Soft Tissue (20) · Neoplasms, Fibrous Tissue (20) · Neoplasms, Glandular and Epithelial (20) · Adnexal Diseases (19) · Endocrine Gland Neoplasms (19) · Endocrine System Diseases (19) · Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Genital Diseases (19) · Genital Diseases, Female (19)
Carboplatin (9) · Paclitaxel (8) · Taxes (6) · Bevacizumab (3) · Cisplatin (3) · Topotecan (3) · Docetaxel (2) · Etoposide (2) · Filgrastim (2) · SS1(dsFv)PE38 (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bortezomib (1) · Chemotherapy, Adjuvant (1) · Disulfides (1) · Erlotinib Hydrochloride (1)
Gynecologic Oncology Group (8) · National Cancer Institute (NCI) (7) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · Columbia University (1)
United States (19) · Canada (2) · Japan (1) · Norway (1)
Peter G. Rose, MD (3) · Don Dizon (2) · Evanthia Galanis, MD (2) · Leona A. Holmberg, MD, PhD (2) · Mark Morgan (2) · Bradley Monk (1) · Bret Taback, MD (1) · Dan Veljovich, MD (1) · Deborah Armstrong (1) · Joan Walker (1) · Katherine M Bell-McGuinn (1) · Michael A. Bookman, MD (1) · Michael Rodriguez, MD (1) · Raffit Hassan, MD (1) · Robert Kreitman, MD (1)
PMID 16412499, PMID 16631245, PMID 16959305, PMID 19671873, PMID 28341300, PMID 31708167, PMID 33610319
U10CA027469 (8), P50CA136393 (2), U10CA180868 (2), P30CA015083 (1), R01CA136547 (1), R01CA200507 (1), R01CA228275 (1), R01CA301199 (1)